Chemokine regulation of atherosclerosis

Oxidative stress and inflammation are accepted as major factors in the pathogenesis of atherosclerosis, but how they interact to produce a plaque has not been delineated clearly. Recent data suggest that oxidized lipids may act in part by regulating production of chemokines and chemokine receptors, which in turn, may direct monocytes and other blood leukocytes to the vessel wall, where they may interact with endothelial cells and smooth muscle cells. The receptors may act at the level of recruitment, retention, and egress, not only through classic, chemotactic mechanisms but also through direct, intercellular adhesion. The results suggest a coordinated mechanism for inflammatory cell accumulation in plaque and identify novel targets, such as CCR2 and CX3CR1, for potential drug development in coronary artery disease.

[1]  T. Lagerweij,et al.  The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice. , 2007, Atherosclerosis.

[2]  Christian Weber,et al.  Ccr5 But Not Ccr1 Deficiency Reduces Development of Diet-Induced Atherosclerosis in Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[3]  Y. Sheikine,et al.  Can CXCL16 be linked to coronary vascular disease? We still know too little … , 2006 .

[4]  P. V. van Riel,et al.  Can CXCL16 be linked to coronary vascular disease? Comment on the article by Sheikine et al. , 2006, Atherosclerosis.

[5]  G. Hansson,et al.  T Cells in Atherogenesis: For Better or For Worse? , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[6]  A. Hamsten,et al.  Decreased plasma CXCL16/SR-PSOX concentration is associated with coronary artery disease. , 2006, Atherosclerosis.

[7]  S. Reddy,et al.  Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention , 2006, Nature Clinical Practice Cardiovascular Medicine.

[8]  D. Patel,et al.  CX3CR1 Deficiency Confers Protection From Intimal Hyperplasia After Arterial Injury , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[9]  P. Murphy,et al.  Oxidized Lipid-Driven Chemokine Receptor Switch, CCR2 to CX3CR1, Mediates Adhesion of Human Macrophages to Coronary Artery Smooth Muscle Cells Through a Peroxisome Proliferator-Activated Receptor γ–Dependent Pathway , 2006, Circulation.

[10]  N. Bresolin,et al.  Candidate gene analysis of IP-10 gene in patients with Alzheimer's disease , 2006, Neuroscience Letters.

[11]  I. Charo,et al.  Targeted Disruption of the Scavenger Receptor and Chemokine CXCL16 Accelerates Atherosclerosis , 2006, Circulation.

[12]  Peter Libby,et al.  The immune response in atherosclerosis: a double-edged sword , 2006, Nature Reviews Immunology.

[13]  J. Mehta,et al.  Suppression of atherogenesis by delivery of TGFbeta1ACT using adeno-associated virus type 2 in LDLR knockout mice. , 2006, Biochemical and biophysical research communications.

[14]  K. Moore,et al.  Chemokine CXCL10 Promotes Atherogenesis by Modulating the Local Balance of Effector and Regulatory T Cells , 2006, Circulation.

[15]  Shigeyoshi Itohara,et al.  Effect of MMP-2 Deficiency on Atherosclerotic Lesion Formation in ApoE-Deficient Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[16]  R. Terkeltaub,et al.  Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. , 2006, The American journal of pathology.

[17]  F. Tacke,et al.  Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Ye Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. , 2006, Cardiovascular research.

[19]  B. Banas,et al.  RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. , 2005, Atherosclerosis.

[20]  P. Tobias,et al.  Modulation of atherosclerosis in mice by Toll-like receptor 2. , 2005, The Journal of clinical investigation.

[21]  H. Shin,et al.  CXCR3 polymorphisms associated with risk of asthma. , 2005, Biochemical and biophysical research communications.

[22]  K. Rakesh,et al.  Cytokines and growth factors involved in apoptosis and proliferation of vascular smooth muscle cells. , 2005, International immunopharmacology.

[23]  J. Hirschhorn,et al.  CCL2 Polymorphisms Are Associated With Serum Monocyte Chemoattractant Protein-1 Levels and Myocardial Infarction in the Framingham Heart Study , 2005, Circulation.

[24]  F. Mach,et al.  Differential Influence of Chemokine Receptors CCR2 and CXCR3 in Development of Atherosclerosis In Vivo , 2005, Circulation.

[25]  R. Schnabel,et al.  Genetic Analysis of the Interleukin-18 System Highlights the Role of the Interleukin-18 Gene in Cardiovascular Disease , 2005, Circulation.

[26]  D. Ramji,et al.  Interferon-g and atherosclerosis : Pro-or anti-atherogenic ? , 2005 .

[27]  S. Anker,et al.  A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis , 2005, Journal of Molecular Medicine.

[28]  A. Hamsten,et al.  Severity of coronary artery stenosis is associated with a polymorphism in the CXCL16/SR‐PSOX gene , 2005, Journal of internal medicine.

[29]  O. Migita,et al.  Association of a haplotype block spanning SDAD1 gene and CXC chemokine genes with allergic rhinitis. , 2005, The Journal of allergy and clinical immunology.

[30]  A. Hajeer,et al.  Polymorphisms of the IL-8 and CXCR2 genes are not associated with Behçet's disease. , 2005, The Journal of rheumatology.

[31]  L. Norgren,et al.  The chemokine and scavenger receptor CXCL16/SR-PSOX is expressed in human vascular smooth muscle cells and is induced by interferon gamma. , 2004, Biochemical and biophysical research communications.

[32]  D. Teupser,et al.  Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[33]  JanNilsson,et al.  Inhibition of Tumor Necrosis Factor-α Reduces Atherosclerosis in Apolipoprotein E Knockout Mice , 2004 .

[34]  L. Hovgaard,et al.  Inhibition of Tumor Necrosis Factor-&agr; Reduces Atherosclerosis in Apolipoprotein E Knockout Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[35]  E. Fisher,et al.  Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. Sakoda,et al.  Critical Roles of CXC Chemokine Ligand 16/Scavenger Receptor that Binds Phosphatidylserine and Oxidized Lipoprotein in the Pathogenesis of Both Acute and Adoptive Transfer Experimental Autoimmune Encephalomyelitis1 , 2004, The Journal of Immunology.

[37]  W. März,et al.  Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. , 2004, European heart journal.

[38]  D. Broide,et al.  IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. , 2004, The Journal of clinical investigation.

[39]  S. Akira,et al.  Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Knud Erik Pedersen,et al.  Regression of Coronary Atherosclerosis by Simvastatin: A Serial Intravascular Ultrasound Study , 2004, Circulation.

[41]  F. Ohsuzu,et al.  Lack of Interleukin-1 Receptor Antagonist Modulates Plaque Composition in Apolipoprotein E–Deficient Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[42]  M. Biondi,et al.  Internal Carotid Artery Occlusive Disease and Polymorphisms of Fractalkine Receptor CX3CR1: A Genetic Risk Factor , 2004, Stroke.

[43]  Frédéric Pincet,et al.  Enhanced Adhesive Capacities of the Naturally Occurring Ile249–Met280 Variant of the Chemokine Receptor CX3CR1* , 2004, Journal of Biological Chemistry.

[44]  U. Hedin,et al.  CXCL16/SR-PSOX Is an Interferon-&ggr;–Regulated Chemokine and Scavenger Receptor Expressed in Atherosclerotic Lesions , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[45]  A. Luttun,et al.  Loss of Matrix Metalloproteinase-9 or Matrix Metalloproteinase-12 Protects Apolipoprotein E–Deficient Mice Against Atherosclerotic Media Destruction but Differentially Affects Plaque Growth , 2004, Circulation.

[46]  P. Dempsey,et al.  A Disintegrin and Metalloproteinase 10-Mediated Cleavage and Shedding Regulates the Cell Surface Expression of CXC Chemokine Ligand 16 , 2004, The Journal of Immunology.

[47]  K. Moore,et al.  Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways , 2004, Nature Medicine.

[48]  J. Fallon,et al.  Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion. , 2004, Blood.

[49]  F. Mach,et al.  Antagonism of RANTES Receptors Reduces Atherosclerotic Plaque Formation in Mice , 2004, Circulation research.

[50]  T. Kita,et al.  Cell surface‐anchored SR‐PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6‐expressing cells , 2004, Journal of leukocyte biology.

[51]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[52]  P. Verpillat,et al.  Association of the Toll-Like Receptor 4 Gene Asp299Gly Polymorphism With Acute Coronary Events , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[53]  D. Greaves,et al.  Smooth Muscle Cells in Human Atherosclerotic Plaques Express the Fractalkine Receptor CX3CR1 and Undergo Chemotaxis to the CX3C Chemokine Fractalkine (CX3CL1) , 2003, Circulation.

[54]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[55]  K. Egashira,et al.  Anti-monocyte chemoattractant protein-1 gene therapy for cardiovascular diseases , 2003, Expert review of cardiovascular therapy.

[56]  P. Tipping,et al.  The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. , 2003, The American journal of pathology.

[57]  F. Fahrenholz,et al.  The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. , 2003, Blood.

[58]  J. Drabek,et al.  CC chemokine receptor (CCR)2 polymorphism in Czech patients with myocardial infarction. , 2003, Immunology letters.

[59]  M. Taubman,et al.  Chemokine Receptors in Vascular Smooth Muscle , 2003, Microcirculation.

[60]  S. Akira,et al.  Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. , 2003, Cardiovascular research.

[61]  I. Charo,et al.  Chemokine Receptor 2 (CCR2) in Atherosclerosis, Infectious Diseases, and Regulation of T‐Cell Polarization , 2003, Microcirculation.

[62]  P. Eriksson,et al.  Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. , 2003, Journal of the American College of Cardiology.

[63]  C. Weber,et al.  Chemokine receptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age , 2003, Journal of Molecular Medicine.

[64]  R. D'Agostino,et al.  Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. , 2003, The Journal of clinical investigation.

[65]  N. Maeda,et al.  CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. , 2003, Atherosclerosis.

[66]  N. Maeda,et al.  Transplantation of Monocyte CC-Chemokine Receptor 2-Deficient Bone Marrow Into ApoE3-Leiden Mice Inhibits Atherogenesis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[67]  K. Egashira Molecular Mechanisms Mediating Inflammation in Vascular Disease: Special Reference to Monocyte Chemoattractant Protein-1 , 2003, Hypertension.

[68]  P. Debré,et al.  Decreased Atherosclerotic Lesion Formation in CX3CR1/Apolipoprotein E Double Knockout Mice , 2003, Circulation.

[69]  E. Antman,et al.  Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes , 2003, Circulation.

[70]  I. Charo,et al.  Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. , 2003, The Journal of clinical investigation.

[71]  G. Cooke,et al.  Toll-like receptor 4 polymorphisms and atherogenesis. , 2002, The New England journal of medicine.

[72]  V. Fuster,et al.  Lipid Lowering by Simvastatin Induces Regression of Human Atherosclerotic Lesions: Two Years’ Follow-Up by High-Resolution Noninvasive Magnetic Resonance Imaging , 2002, Circulation.

[73]  B. McManus,et al.  Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. , 2002, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[74]  D. Rader,et al.  Val64Ile Polymorphism in the C-C Chemokine Receptor 2 Is Associated With Reduced Coronary Artery Calcification , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[75]  M. Biondi,et al.  Matrix Metalloproteinase-1 and Matrix Metalloproteinase-3 Gene Promoter Polymorphisms Are Associated With Carotid Artery Stenosis , 2002, Stroke.

[76]  D. Niederacher,et al.  C/T polymorphism of the intercellular adhesion molecule-1 gene (exon 6, codon 469). A risk factor for coronary heart disease and myocardial infarction. , 2002, International journal of cardiology.

[77]  A. Daugherty,et al.  IFN-gamma deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/- mice. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[78]  P. Murphy International Union of Pharmacology. XXX. Update on Chemokine Receptor Nomenclature , 2002, Pharmacological Reviews.

[79]  M. Daemen,et al.  Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[80]  J. Badimón,et al.  CCR2 Deficiency Decreases Intimal Hyperplasia After Arterial Injury , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[81]  Yong-wen Qin,et al.  OxLDL upregulates CXCR2 expression in monocytes via scavenger receptors and activation of p38 mitogen-activated protein kinase. , 2002, Cardiovascular research.

[82]  笹岡 大史 Polymorphisms in the platelet-endothelial cell adhesion molecule-1 (PECAM-1) gene, Asn563Ser and Gly670Arg, associated with myocardial infarction in the Japanese , 2002 .

[83]  T. Kita,et al.  Expression of Scavenger Receptor for Phosphatidylserine and Oxidized Lipoprotein (SR‐PSOX) in Human Atheroma , 2001, Annals of the New York Academy of Sciences.

[84]  A. Kimura,et al.  Polymorphisms in the Platelet‐Endothelial Cell Adhesion Molecule‐1 (PECAM‐1) Gene, Asn563Ser and Gly670Arg, Associated with Myocardial Infarction in the Japanese , 2001, Annals of the New York Academy of Sciences.

[85]  E. Fisher,et al.  Elevating High-Density Lipoprotein Cholesterol in Apolipoprotein E—Deficient Mice Remodels Advanced Atherosclerotic Lesions by Decreasing Macrophage and Increasing Smooth Muscle Cell Content , 2001, Circulation.

[86]  B. Rollins Chemokines and atherosclerosis: what Adam Smith has to say about vascular disease. , 2001, The Journal of clinical investigation.

[87]  Steffen Jung,et al.  The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. , 2001, The Journal of clinical investigation.

[88]  Masashi Komeda,et al.  Expression of SR-PSOX, a Novel Cell-Surface Scavenger Receptor for Phosphatidylserine and Oxidized LDL in Human Atherosclerotic Lesions , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[89]  C. Blobel,et al.  Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). , 2001, The Journal of biological chemistry.

[90]  S. Reddy,et al.  Increased Transcription of IL-8 in Endothelial Cells Is Differentially Regulated by TNF-&agr; and Oxidized Phospholipids , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[91]  Z. Fayad,et al.  Dramatic remodeling of advanced atherosclerotic plaques of the apolipoprotein E-deficient mouse in a novel transplantation model. , 2001, Journal of vascular surgery.

[92]  Z. Prohászka,et al.  Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. , 2001, Atherosclerosis.

[93]  A. Quyyumi,et al.  Association Between Polymorphism in the Chemokine Receptor CX3CR1 and Coronary Vascular Endothelial Dysfunction and Atherosclerosis , 2001, Circulation research.

[94]  V. Álvarez,et al.  Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction , 2001, Genes and Immunity.

[95]  C. Kataoka,et al.  New Anti-Monocyte Chemoattractant Protein-1 Gene Therapy Attenuates Atherosclerosis in Apolipoprotein E-Knockout Mice , 2001, Circulation.

[96]  D. Soler,et al.  Expression Cloning of the STRL33/BONZO/TYMSTR Ligand Reveals Elements of CC, CXC, and CX3C Chemokines , 2001, The Journal of Immunology.

[97]  P. Debré,et al.  Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. , 2001, Blood.

[98]  D. Grobbee,et al.  Homozygosity for 807 T Polymorphism in α2 Subunit of Platelet α2β1 Is Associated With Increased Risk of Cardiovascular Mortality in High-Risk Women , 2000 .

[99]  Andrew C. Li,et al.  Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. , 2000, The Journal of clinical investigation.

[100]  M. Koschinsky,et al.  CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. , 2000, Circulation.

[101]  Y. Chao,et al.  Infectious Agents Are Not Necessary for Murine Atherogenesis , 2000, The Journal of experimental medicine.

[102]  P. Groot,et al.  Localisation of mRNA for JE/MCP-1 and Its Receptor CCR2 in Atherosclerotic Lesions of the ApoE Knockout Mouse , 2000, Journal of Vascular Research.

[103]  Weixin Zhao,et al.  Human Vascular Smooth Muscle Cells Possess Functional CCR5* , 2000, The Journal of Biological Chemistry.

[104]  U. Wahn,et al.  Atopic Dermatitis Is Associated with a Functional Mutation in the Promoter of the C-C Chemokine RANTES1 , 2000, The Journal of Immunology.

[105]  P. Libby,et al.  Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. , 1999, The Journal of clinical investigation.

[106]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[107]  C. Kessler,et al.  The 2 Gene Coding Sequence T807/A873 of the Platelet Collagen Receptor Integrin 2β1 Might Be a Genetic Risk Factor for the Development of Stroke in Younger Patients , 1999 .

[108]  G. Baumann,et al.  Functional Characterization of Atherosclerosis-Associated Ser128Arg and Leu554Phe E-Selectin Mutations , 1999, Biological chemistry.

[109]  B. Rollins,et al.  Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[110]  C. Iwai,et al.  Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. , 1999, Circulation.

[111]  O. Quehenberger,et al.  Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function. , 1999, Journal of lipid research.

[112]  K Fukutake,et al.  Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[113]  B. Rollins,et al.  MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. , 1999, The Journal of clinical investigation.

[114]  N. Camp,et al.  Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. , 1999, Circulation.

[115]  B. Lämmle,et al.  Association of two silent polymorphisms of platelet glycoprotein la/lla receptor with risk of myocardial infarction: a case-control study , 1999, The Lancet.

[116]  B. Rollins,et al.  Monocyte chemoattractant protein-1. , 1999, Chemical immunology.

[117]  O. Quehenberger,et al.  Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes. A regulatory role for plasma LDL. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[118]  I. Charo,et al.  Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.

[119]  P. Libby,et al.  Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. , 1998, Molecular cell.

[120]  D. Arveiler,et al.  The P-selectin gene is highly polymorphic: reduced frequency of the Pro715 allele carriers in patients with myocardial infarction. , 1998, Human molecular genetics.

[121]  A. Roach,et al.  Human vascular smooth muscle cells express receptors for CC chemokines. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[122]  R. Terkeltaub,et al.  A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. , 1998, The Journal of clinical investigation.

[123]  Robert V Farese,et al.  Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. , 1997, The Journal of clinical investigation.

[124]  T. Schall,et al.  Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion , 1997, Cell.

[125]  B. Rollins,et al.  In vivo properties of monocyte chemoattractant protein‐1 , 1997, Journal of leukocyte biology.

[126]  A. Tall,et al.  IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. , 1997, The Journal of clinical investigation.

[127]  J. Farber Mig and IP‐10: CXC chemokines that target lymphocytes , 1997, Journal of leukocyte biology.

[128]  Wei Wang,et al.  A new class of membrane-bound chemokine with a CX3C motif , 1997, Nature.

[129]  P. Huie,et al.  RANTES chemokine expression in transplant-associated accelerated atherosclerosis. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[130]  P. Tipping,et al.  Interleukin-8 production by macrophages from atheromatous plaques. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[131]  A. Henney,et al.  Progression of Coronary Atherosclerosis Is Associated with a Common Genetic Variant of the Human Stromelysin-1 Promoter Which Results in Reduced Gene Expression* , 1996, The Journal of Biological Chemistry.

[132]  B. Rollins Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. , 1996, Molecular medicine today.

[133]  R. Warnke,et al.  RANTES chemokine expression in diseased and normal human tissues. , 1996, Cytokine.

[134]  S M Schwartz,et al.  The intima. Soil for atherosclerosis and restenosis. , 1995, Circulation research.

[135]  F. Neumann,et al.  Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. , 1995, Circulation.

[136]  D. Taub,et al.  Modulation of IL‐8 receptor expression on purified human T lymphocytes is associated with changed chemotactic responses to IL‐8 , 1995, Journal of leukocyte biology.

[137]  S. Murakami,et al.  Expression of both types of human interleukin‐8 receptors on mature neutrophils, monocytes, and natural killer cells , 1995, Journal of leukocyte biology.

[138]  L. F. Kolakowski,et al.  The murine interleukin 8 type B receptor homologue and its ligands. Expression and biological characterization. , 1994, The Journal of biological chemistry.

[139]  M. Kendall,et al.  The oxidation hypothesis of atherosclerosis , 1994, The Lancet.

[140]  G. Baumann,et al.  E-selectin polymorphism and atherosclerosis: an association study. , 1994, Human molecular genetics.

[141]  T. Yue,et al.  Interleukin-8. A mitogen and chemoattractant for vascular smooth muscle cells. , 1994, Circulation research.

[142]  S. Coughlin,et al.  Monocyte chemoattractant protein-1 in human atheromatous plaques. , 1991, The Journal of clinical investigation.

[143]  D. Steinberg,et al.  Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[144]  R. Ross,et al.  The role of endothelial injury and platelet and macrophage interactions in atherosclerosis , 1984, Circulation.

[145]  R. Ross,et al.  ENDOTHELIAL INJURY: BLOOD‐VESSEL WALL INTERACTIONS * , 1982, Annals of the New York Academy of Sciences.